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ABSTRACT 
 
This Thesis was made with the intention to mechanistically assess and further develop a multi-
stage cell line-based (in vitro) model for oral cancer development. Efforts of establishing 
additional tumor cell lines for expanding the model were coupled with the application of 
systems biology technologies for characterization of the three entities of the start-up model, 
including: 1) normal, 2) immortal and non-tumorigenic, versus 3) immortal and tumorigenic 
stages. Omics data integration from assessment of cell lines as unique entities, and model-
driven in vitro manipulations formed the basis for construction of two bioinformatics-based 
pipelines for this task. Altered phenotypic and genotypic characteristics and the event of non-
functional cell differentiation (a hallmark of cancer development) was analyzed broadly 
among the transformed stages of the model relative the normal counterpart, testing the 
overarching hypothesis that thorough analysis of cell line data might contribute clinically 
useful tumor biomarkers potentially hidden in existing genome-wide assessments of clinical 
tissue samples.  
 
The separate papers forming the Thesis, in order, generated: 1) a review of existing data from 
the start-up model under a selected standardized serum-free condition, 2) an omics-integrative 
tumor biomarker discovery pipeline based on the start-up model, 3) a model-driven tumor 
biomarker discovery pipeline based on assessment of influences of confluency (high cell 
density and cell-to-cell contact) in the seemingly most differentiation-deficient cell line in the 
start-up model, 4) a novel tumor cell line applicable to expand the number of serum-free 
entities of the model, 5) an expanded model-driven tumor biomarker discovery pipeline based 
on assessment of serum-induced influences of the extended model (now with four entities), 
and finally, 6) an analysis of the novel cell line under a further expanded omics-integrative 
tumor biomarker discovery pipeline. The overall results included broad description of the 
multiple alterations at gene, pathway and ontology levels that coupled with the transformed 
phenotypes and non-functional cell differentiation in the cell line models. The bioinformatics-
driven assessment using overall six different processing tools of differential expression of 44 
proteins and thousands of transcripts from these analyses suggested multiple potential 
biomarker signatures in head and neck squamous cell carcinoma. Overall, five in vitro-based 
signatures could be validated for clinical significance in independent data from tumor tissue 
analysis, including multiple oral and non-oral patient data sets as well as body-wide 
transcriptomics and proteomics expression databases. The taken approaches elucidated basic 
mechanisms of cell transformation while simultaneously generating paradigms/protocols 
generally applicable to cancer biomarker discovery. Proving the hypothesis under testing, the 
results show that the in vitro-derived biomarkers are complementary, often with superior 
accuracy, to those generated from direct assessment of cancer tissue specimens. Overall, the 
application of technologies and methods as described possibly generated a first description of 
an “in vitro systems biology model of oral cancer development” with potential for wide further 
application in experimental and translational research.  
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1 INTRODUCTION 
1.1 THE BIOLOGICAL FATE OF KERATINOCYTES 
1.1.1 The oral mucosa – structure and function 
The oral mucosa serves as a barrier to maintain tissue homeostasis and protect the 
underlying tissue from environmental factors such as bacterial, chemical and physical 
agents (1). The oral epithelium, encompassing several layers of keratinocytes, creates 
the surface of the oral mucosa, and it is supported by adjacent connective tissue, the 
lamina propria. Based on morphology and differentiation patterns, the oral mucosa can 
be divided into three major parts (2, 3). First, the major surface area of the oral mucosa 
encompasses the lining mucosa, a non-keratinized, stratified squamous epithelium that 
includes the buccal mucosa and floor of the mouth. Second, the masticatory mucosa, a 
keratinized, stratified squamous epithelium, includes the dorsum of the tongue, hard 
palate and gingival mucosa. Third, the specialized mucosa encompasses the taste buds 
on the dorsal surface of the tongue. The current thesis has primarily focused on the 
lining mucosa for the in vitro studies, encompassing around 60% of the total surface 
area of the oral lining, and therefore serves as an important target for carcinogen 
exposure and subsequent cancer development in the head and neck region (4-6). The 
lining mucosa, can be further divided into three layers; [1] the inner basal layer that 
attach to the basement membrane and contain stem cells and undifferentiated, mitotic 
keratinocytes [2] the intermediate layer that contains maturing and migrating 
keratinocytes that eventually end up in [3] the superficial layer that contains flattened, 
terminally differentiated cells (1, 7). A majority of the oral epithelium encompasses 
keratinocytes, but other cell types are also present such as Langerhans cells, Merkel 
cells and inflammatory cells (3). The migration and maturation from the basal layer to 
the upper layers take 14-20 days for the lining mucosa, and the keratinocytes eventually 
lose their proliferative potential as they move up in the epithelial layers and become 
terminally differentiated (3). The function and balance between these layers is disrupted 
during in cancer development.            
 
1.1.2 Terminal differentiation  
A balance between cell growth and cell death is essential for proper development of the 
tissue (3, 8). Terminal differentiation (TD) represents the primary biological fate for 
cell death in the oral epithelium (1, 7, 8). Migration of the basal keratinocytes to the 
upper layers to form the cross-linked protein envelope, which serves as a protective 
layer, associates with a multifaceted differentiation program. This transition is 
 2 
accompanied by morphological changes, cytoskeletal rearrangements and influences on 
other biological fates such as proliferation and apoptosis (1, 3, 8). Expression of 
cytokeratins (CK), structural proteins that form intermediate filaments, is determined 
by the differentiation stage (1, 7) Keratinocytes in the basal layer primarily express 
CK5, CK14 and CK19, while the upper layers express CK4 and CK13. Constituents of 
the cross-linked envelope, e.g., involucrin, small-proline rich protein 1 and 3, and 
transglutaminase 1 increase in expression as the cells start to differentiate (1, 3). 
Involucrin in particular serves as a marker for commitment to terminal differentiation 
(9). Initiation in differentiation circuits lead to decreased proliferation in order to 
maintain the tissue homeostasis (8). This balance is perturbed in immortalized cells due 
to terminal differentiation resistance (10). There are numerous components that 
regulate normal tissue homeostasis including growth factors, adhesion molecules and 
toxicants (3). Means of inducing TD in vitro include, serum factors (e.g., Ca
2+
, retinoic 
acid, vitamin D3, and transforming growth factor-β), confluency (high cell density and 
cell-to-cell contact) tumor promoting factors (e.g., 12-O-tetradecanoylphorbol-13-
acetate) and toxicants (e.g., aldehydes) (11-16). To mirror the complete differentiation 
program that emerges in vivo, different means of inducing TD in vitro are likely 
needed. The importance of perturbations in differentiation circuits for head and neck 
squamous cell carcinoma (HNSCC) pathogenesis was recently emphasized by whole-
exome sequencing of 74 tumor specimens where 30% of the mutational landscape 
involved genes regulating differentiation (17). These findings indicate that similar to 
previous knowledge on p53 inactivation, which is consistent among this heterogeneous 
malignancy, aberrances in the differentiation program seem equally comprehensive for 
HNSCC carcinogenesis (17-19).     
 
1.1.3 Apoptosis  
Despite previous perplexity regarding the distinction between apoptosis and TD, it is 
now established that these processes represent separate cellular fates, even if some 
molecular features are similar (8). Apoptosis is characterized by cytoplasmic 
condensation and plasma membrane blebbing generating apoptotic bodies that can be 
recognized and engulfed by macrophages (20). The apoptotic process can be initiated 
by the extrinsic or intrinsic pathway. The extrinsic pathway is activated by binding of 
a ligand to a death receptor (e.g., Fas) that triggers a caspase (CASP) cascade 
(CASP8 and CASP3) resulting in cell degradation. The intrinsic pathway is activated 
upon cellular stress (e.g., DNA damage) by the release of pro-apoptotic factors such 
as cytochrome c from the mitochondria. Binding of cytochrome c to the apoptotic 
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protease-activating factor-1 activates a caspase cascade (CASP9 and CASP3) 
resulting in cell degradation (20). There are several regulators of apoptosis acting 
either in a pro-apoptotic (e.g., BAX, BAK) or anti-apoptotic (e.g., BCL2, BCL2L1, 
MCL1) manner. Although apoptosis and terminal differentiation involve some similar 
signal transduction pathways, the activation patterns of the involved transcription 
factors and proteins differ clearly on the mechanistic level (8). For example, TP53 is 
imperative for apoptosis in response to cellular stress such as DNA damage, while the 
family member TP63 is central for terminal differentiation (8, 17). Second, caspases 
are crucial for execution of both the intrinsic and extrinsic pathway, but appear to 
have less relevance for differentiation, despite the involvement of CASP14 in 
formation of the outermost layer of the skin (20, 21). Recent mutational profiling 
does however display that 8% of the assessed HNSCC samples harbor mutations in 
CASP8 (17).                           
 
1.1.4 Head and neck / oral carcinogenesis  
Head and neck cancer is a broad term applied for cancers in the oral cavity, pharynx 
and larynx and it is the sixth most common cancer worldwide (5, 22, 23). More than 
90% of the tumors are of epithelial origin and about 50% establish in the oral mucosa 
(24). Known risk factors include alcohol consumption, tobacco usage and human 
papilloma virus (HPV) infections (5, 18, 22). Patients are currently diagnosed by 
clinical examination, radiology and histopathological staging. Despite recent advances 
in aggressive multidisciplinary treatment approaches, including surgery, chemotherapy 
and radiotherapy, the mortality rate is still around 50% after 5 years and patients 
develop locoregional recurrences, distant metastasis and second primary tumors (5). 
The extensive molecular heterogeneity of HNSCC provides an additional level of 
biological complexity for prognosis and treatment, including utilization of targeted 
therapies, emphasizing the importance of developing molecular markers for 
individualized treatment (25-27). To date, there are no molecular tests that provide 
higher diagnostic accuracy compared to the conventional pathological scoring methods 
(28).  
  
Carcinogenesis in the head and neck region is a multi-step process by which genes and 
pathways acquire genetic and epigenetic changes that enable a transition from a normal 
epithelium to an invasive carcinoma via dysplasia and carcinoma in situ (5, 10, 18, 22). 
Recently reviewed by Hanahan and Weinberg, cancer development is generally typified 
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by a set of biologically distinguishable hallmarks (29). These hallmarks can be 
translated to HNSCC development and include: 
- Evasion of growth suppression,  by mutations and altered expression of the cell 
cycle regulators TP53, CCND1 and CDKN2A in primarily HPV-negative HNSCC, 
while HPV positive cancers display changes in TP53 and the Rb family genes (18).  
- Self-sufficiency in growth signals, by increased expression of the epidermal growth 
factor receptor, also serving as a marker of early carcinogenesis and predictor for poor 
outcome (30-32).  
- Insensitivity to anti-growth signals, by down-regulation of the growth inhibitory 
transforming growth factor β (TGF- β), for example via down-regulation of disabled 
homolog 2 permitting TGF-β mediated cell motility and tumor growth (33). 
- Evasion of cell death, by mutations in terminal differentiation-associated genes (e.g., 
IRF6, TP63, NOTCH1, RIPK4) and apoptotic genes (e.g., TP53, PTEN, CASP8, and 
PIK3CA) (17, 19).  
- Invasion and metastasis, via alterations in genes involved in epithelial-mesenchymal 
transition, such as the hub-gene E-cadherin, to acquire plasticity and facilitate migration 
(34).  
- Induction of angiogenesis, by increasing the vascular endothelial growth factor 
receptor expression, which associates with poor outcome (35)  
- Reprogramming of metabolism, by expression of mutant mitochondrial DNA 
(NADH dehydrogenase subunit 2) which induces reactive oxygen species production, 
aerobic glycolysis and tumor growth (36).  
- Immune escape, by increased expression of STAT3, resulting in suppressed 
expression and excretion of proinflammatory cytokines and chemokines (37).  
 
Genetic instability in the cancer cells is also an important feature for driving the multi-
step progression from normal to tumorigenic (5, 29).   
                  
1.1.5 In vitro models for head and neck / oral carcinogenesis  
Cell lines constitute a renewable source of well-defined starting material for exploring 
carcinogenesis and biomarkers. The epithelia constitute the major target for tumor 
development (5). Multiple cell line models exist for head and neck carcinogenesis 
studies, where the absolute majority applies serum to the culture conditions (38, 39). 
Differently, most recent methods for culture of cell lines from normal (non-
transformed) tissue employ serum-free conditions (11, 40). Thus, the comparison of 
normal and transformed states is commonly hampered by cultivation of the respective 
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cell phenotypes in different conditions. Interestingly, normal, proliferative and basal-
like cells in culture undergo terminal differentiation when exposed to serum, typically 
fetal bovine serum (FBS) (11, 15, 16). Normal cells in culture are typified by a finite 
lifespan, and thus laboratory-based efforts for immortalization of cells, or generating 
lines from tumor tissue, have been beneficial to acquire renewable, broadly applicable 
sources of cell lines (11, 41, 42). Of particular importance to this thesis project, the 
transformed systems proliferate reproducibly on the basis that they are unable to 
undergo TD (10). Considering a central role of perturbed differentiation in HNSCC 
carcinogenesis, and the inability of transformed cells to undergo their normal and most 
common cellular fate, argues against the application of transformed model systems 
only (10, 17). Cancer development, even at its early stages, may also involve altered 
regulation of other cellular fates such as apoptosis (8, 20). The definition of whether, 
and to what extent, cell line models are proficient of relevant forms of cell death 
therefore needs to be addressed at genomic and functional level.             
 
Limited cell lines are available for modeling the intermediary stages in cancer 
progression, mainly because cancers that establish in vitro associate with poor 
prognosis (43). Immortalization is a crucial step in the transformation of normal cells. 
Efforts to laboratory-immortalize normal keratinocytes have primarily been made using 
viral oncogenes such as Simian virus 40 (SV40) and HPV that perturb the p53 and Rb 
pathways (42, 44). Viral oncogene immortalization generates predominantly non-
tumorigenic cell lines (38). Alterations of other cancer-associated genes for 
immortalization are successfully demonstrated by cyclin D1 overexpression and p53 
inactivation, however failing to produce growth in soft agar and tumors in nude mice 
(45, 46). Additional overexpression of epithelial growth factor receptor and c-myc as 
well as telomerase reactivation is needed for complete transformation generating 
colonies in soft agar and tumors in immunodeficient nude mice (46).  
 
To avoid the complication that arises from differing culture conditions, a triad of model 
systems, i.e., normal oral keratinocytes (NOK), the SV40 T-antigen immortalized line 
SVpgC2a and the carcinoma line SqCC/Y1 have been utilized for in vitro modeling of 
oral carcinogenesis under a standardized serum-free condition (Figure 1, and reviewed 
in PAPER I). NOK cultures from the mucosal lining are typically derived from biopsies 
of patients undergoing maxillofacial surgery (47). In vitro cultures of NOK aim at 
deriving highly proliferative and basal-like cells that include a low number of oral 
keratinocyte stem cells, among a pre-dominant population of transiently-amplifying 
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progenitor cell that eventually commit to terminal differentiation, in particular from 
stimuli such as confluency culture (high cell density and cell-to-cell contact) and from 
exposure to FBS at levels of 2 to 10% supplementation (11, 15, 16).  
The SVpgC2a cell line was derived from transfection of SV40 T-antigen to NOK from 
a female donor, resulting in a number of different cell lines with extended longevities 
(42). One of these cell lines survived two crises that resulted in the establishment of the 
SVpgC2a cell line. The SVpgC2a cell line is immortal (cultured for >150 passages), 
non-tumorigenic when injected into nude mice and highly terminal-differentiation 
deficient (42). The SqCC/Y1 cell line was originally derived from a verruous squamous 
cell carcinoma of a female donor using a standard serum-containing medium. 
Adaptation of the culture to serum-free media required two months of culture effort, 
including signs of crises after three weeks, for generation of the serum-free strain of 
SqCC/Y1 (41). The SqCC/Y1 cell possesses an immortal, terminal differentiation-
deficient and tumorigenic phenotype. 
 
Figure 1. Morphologies and key features of normal and transformed oral keratinocytes 
in the start-up model grown in monolayer under standardized serum-free conditions 
Major characteristics of the cell line model were summarized in PAPER I   
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1.2 “OMICS” AND BIOINFORMATICS ANALYSES 
1.2.1 Cancer systems biology  
The definition and application of the term “systems biology” covers technological, 
infrastructural as well as philosophical aspects (48-50). Systems biology aims at 
providing a holistic view of biological systems by multi-disciplinary integration of data 
from different technological platforms and experimental sources. The human genome 
project with subsequent development of high-throughput technologies for genomics, 
transcriptomics, proteomics and metabolomics enable generation of global data sets 
from cells and tissues. Novel integrative tools are needed to interpret and decipher the 
true biology from noise in these huge data sets, requiring multi-disciplinary 
collaboration and appropriate infrastructure (48, 51). Systems biology argues for a 
philosophical shift in the way we perceive biological systems, moving from a 
reductionist approach by assessment of individual components in the cells, to a 
systems-oriented approach, where components and networks are put together (49).             
 
“Cancer systems biology” then adds further complexity (50). Cancer is a heterogeneous 
disease with a strong genetic component (29). It is well recognized that different 
mutations in various molecular pathways take place in a multi-step progression towards 
cancer development, including for HNSCC (5, 18, 22, 29). To elucidate the pathways 
that make a cancer cell functionally aberrant from normal cells and the interrelationship 
of the perturbed pathways, integration of different cellular level data is crucial (52). 
Cancer genome sequencing effort have shown that the number of mutations vary 
considerably between different tumor types, including inter tumor heterogeneity (53, 
54). The mutational spectrum in HNSCC displays on average 130 mutations, and 25 % 
of these mutations seem to appear consistently (17). Despite a general low overlap, 
mutations are believed to alter expression of genes within similar functional classes 
(gene ontologies) or pathways leading to the hallmarks associated with cancer (29, 54, 
55). There are several systems approaches using cancer omics data for delineating 
perturbed networks in tumors, as well as for prediction of poor outcome (56-58). 
Limited systems biology-based approaches for elucidation of mechanisms underlying 
transformation and diagnostics are available for head and neck cancer (59, 60). The 
ultimate goal of systems biology is taking the concepts to the clinic for application of 
systems medicine to eventually enable a more personalized cancer diagnosis and 
therapy (61-63). To achieve this goal, there is a need to elucidate if deregulated 
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molecular networks can associate genes and signatures with higher precision for 
potentially forecasting the multiple sides of prognosis and treatment.   
 
1.2.2 Transcriptomics 
1.2.2.1 A technological overview 
The transcriptome is defined as the relative expression levels of the complete set of 
transcripts in a cell or a tissue. The microarray technology allows for analysis of 
thousands of genes simultaneously and provides a biological snap-shot of the transcript 
levels in the cell at a particular time or condition (64). Microarray analysis has broad 
range of application areas and has served as a powerful tool for e.g., hypothesis 
generation, sample classification, and clinical assessments. The basic principle 
underlying all microarray analyses is the presence of a variable number of nucleotides 
(the probes) corresponding to the respective genes on an array surface and subsequent 
addition of “sample” messenger RNA, which has been labeled with some fluorescent 
dye (64, 65). The amount of sample hybridizing to each probe is proportional to the 
abundance of the transcript, which is detected by the intensity of the dye, corresponding 
to the signal. Two different types of arrays are available for assessment of transcript 
levels. Two-channel arrays are characterized by hybridization of two samples labeled 
with different fluorescent dyes to the same array, and differential gene expression is 
calculated from the relative intensity of each fluorophore bound to the respective 
probes (65). In contrast, one-channel, oligonucleotide arrays only involve hybridization 
of one sample per array, and differential gene expression is obtained from probe 
intensity comparisons relative another array with the same probe setup, hybridized with 
a different sample of interest (66). The latter type was applied for the work in this 
thesis, in particular the Affymetrix technology (Santa Clara, CA). Each probe on the 
Affymetrix chips contains 25 nucleotides targeting the 3’-end of genes, which are 
spotted on a silica substrate using a photolithographic technique that enables production 
of high-density arrays (66-68). Eleven pairs of oligonucleotide probes are utilized to 
measure the abundance of each transcript to correct for unspecific binding. In addition, 
a mismatch probe is available for every perfect match probe, which is represented by a 
nucleotide at the 13
th
 position. This is later taken into account for certain pre-processing 
methods (69).  
 
1.2.2.2 Experimental design 
The experimental design is fundamental for successful microarray studies since the 
amount of data generated is enormous. The first important issue to consider is the level 
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of replication, usually reflected by the biological question and funding. There are two 
major types of replication i.e., biological and technical (70). Biological replicates refer 
to independent samples from the same cell line or tissue. In general, analyses of normal 
cell and tissue samples encompass a larger interindividual variation compared to cells 
in culture, hence require more biological replicates (71). Technical replicates refer to 
repeated analyses of the same biological sample, however with today’s technological 
advances this is of less importance (72). Following RNA isolation, labeling, 
hybridization and scanning of the arrays, the statistical processing and data mining 
commences To this end, replicates are also important for obtaining proper power in the 
downstream analyses.  
 
1.2.2.3 Pre-processing – the path towards finding the actual biological effects   
The first step towards revealing true biological differences between selected 
comparisons, while reducing technical differences, is the pre-processing that 
encompass background correction, normalization and summarization of the probe sets 
(73). Background correction primarily serves to adjust for background noise and un-
specific binding, allowing the expression values to cover a suitable range. The 
normalization serves to reduce the non-biological variation within or between arrays, 
while the summarization generates a final probe set value corresponding to a single 
gene on the array. There are various methods to implement these steps, but the studies 
in this thesis primarily applied the MicroArray Suite (MAS 5.0) algorithm and the 
Robust Multi-array Average (RMA) (69, 74). The MAS 5.0 applies a background 
correction that divides the array into 16 regions; the mean intensity of the lowest 2% of 
the signal spot for each region is calculated, to provide a weighted sum of the zone 
background, which is further subtracted from each spot. The Tukey biweight robust 
median then is utilized for deriving a signal value for mismatch probes and perfect 
match probes, which are then subtracted from each other to obtain gene-specific probes 
on the array (69). This is followed by a global scaling for the individual arrays to a set 
value. The RMA algorithm applies a global background correction, quantile 
normalization and a robust linear model (median polish) for summarization. This 
method only takes perfect match probes into account (74). To date, there is no golden 
standard regarding which method to apply, and evaluation studies provide different 
results (75-77). Image analysis is also an important step in the pre-processing, 
commonly performed using software provided by the array company. Further quality 
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control measures are available on the Affymetrix array to assess amplification, labeling 
and hybridization (73, 78).   
 
1.2.2.4 Statistical tests to enable identification of differently expressed genes 
Similar to the pre-processing step, there are various methods to find significantly 
differentially expressed genes between the analyzed samples. Microarray studies 
typically include small sample sizes from which enormous amounts of data points are 
generated, and this poses a challenge for statistical testing (79, 80). Parametric tests 
such as t-tests are commonly applied, but require assumptions regarding the distribution 
of the data. Since microarray data may be noisy, nonparametric test may therefore be 
more applicable e.g., the Wilcoxon signed-rank test, but can also be less sensitive 
compared to the parametric tests. Other tests include Significance Analysis of 
Microarray that applies a similar method to t-tests, although making fewer assumptions 
regarding the data distribution. It performs permutations of repeated measurements to 
estimate the false discovery rate (81). This correction for multiple testing is useful for 
decreasing the identification of false-positive genes. The limma package in 
R/Bioconductor is also applicable and performs a linear model fit on the data, 
calculates a moderated t-statistics and to give a stable estimate for small sample sizes, 
an empirical Bayes step is used (82). Different statistical tests may provide different 
answers, and the overlap between the methods is sometimes limiting (83). Subsequent 
data mining is therefore important since the differential expression of groups of genes 
likely reflect the biology more accurately compared to single genes.  
   
1.2.3 Proteomics 
The proteome is defined as the complete set of proteins expressed in a cell or tissue. 
Proteomics analyses enable assessment of biological programs that are executed, while 
transcriptomics analyses provide an overview of all ongoing processes. While the 
human genome codes for approximately 20 000 to 25 000 genes, the proteome is much 
larger due to post-translational modifications such as phosphorylation, acetylation and 
cleavage likely generating millions of different proteins (84, 85). Assessment of global 
protein profiles is still a technical challenge compared to transcriptomics, even under 
circumstances of rapid technological methods development (86). Proteomics 
methodologies can be divided into two groups, the first assumes no prior knowledge on 
the identity of the protein and the second assumes prior knowledge on the protein 
identity.  
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1.2.3.1 Methods for finding proteins with unknown identity  
Two dimensional gel electrophoresis and mass spectrometry are commonly used for 
global profiling of unknown proteins. The two dimensional electrophoresis separate the 
sample in two dimensions, the first according to charge by isoelectric focusing and the 
second according to molecular weight by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (87). Subsequent separation, proteins are detected by reversible post-
electrophoresis methods such as coomassie blue or silver staining, resulting in spots 
that correspond to the respective proteins. The spot sizes are quantified digitally for 
detection of differently expressed protein using specific image software such as 
PDQuest (Bio-Rad, Hercules, CA) (88). A mass spectrometer, including an ionizing 
source, an analyzer and a detector, is subsequently applied to identify the proteins by 
converting neutral molecules to ions and separating them by their mass to charge ratio 
in an electromagnetic field (89). For example, the matrix-assisted laser desorption-
ionizing time-of-flight (MALDI-TOF) mass spectrometry analysis generates peptide 
fragments with various molar masses that are compared to theoretical peptide 
fragments in databases for identification of the right protein (90). Gel-based methods 
are difficult from a technical perspective and have a fairly low dynamic range, affecting 
the sensitivity (87). Several non-gel based techniques employing high-performance 
liquid chromatography are currently being developed including improved 
quantification using isotope labeling for enhanced reproducibility and dynamic range 
(86). To this end, global proteomics methods provide means to identify high abundance 
proteins, yet low abundance transcripts are still difficult to detect (91, 92). Moreover, 
the correlation between protein and transcript abundance is low, while higher 
correlations are identified for functional categories (93-95). Novel bioinformatics 
processing approaches are needed to bridge the gap between protein and transcript data 
for potential alleviation of limitations with both methodologies.     
 
1.2.3.2 Methods for finding proteins with known identity  
Under circumstances when the protein is known, several antibody based techniques are 
available e.g., immunohistochemistry, Western blot and tissue microarray. Tissue 
microarrays enable simultaneous assessment of up to 1000 specimens, initially 
collected from individual paraffin-embedded tissue samples for assembly onto a 
common-paraffin block (96). The latter can be cut into hundreds of sections for 
individual assessment of various proteins on the complete tissue set. Tissue microarray 
coupled with immunohistochemistry is a powerful high throughput technology 
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enabling generation of for example a proteomics in silico tool (96-98). Specific 
antibodies are a limiting factor for this method.  
           
1.2.4 Bioinformatics: protocols, tools and databases 
Bioinformatics can be defined as the application of computational and informatics 
technologies to biology and medicine (99). Bioinformatics analyses commonly take 
two paths either “supervised” implying application of prior knowledge to drive the 
analyses or “unsupervised” referring to analyses without prior knowledge (100). 
Analyses of omics data tend to start with “unsupervised” approaches to obtain an 
overview of the complete set of generated data. Hierarchical cluster analyses can be 
applied to sort samples and genes, allowing visualization of patterns and trends in two 
dimensions (101) . Different distance metrics and linkage rules are utilized to organize 
the data and depending on selected method, diverse cluster tress may appear from the 
same data set (102). Commonly applied distance or correlation metrics include the for 
example the Euclidian distance or the Pearson correlation. To compare the nodes, 
different linkage rules are applied e.g., single linkage or average linkage. Refined 
clustering approaches are also available where the number of clusters is pre-defined, 
e.g., self-organizing maps and k-means clustering. Principal components analysis is an 
alternative applicable method for multidimensional data reduction and visualization 
that does not rely on pairwise comparisons (103). “Supervised” approaches comprise 
support vector machine (primarily for sample classification) as well as assessment of 
genes with known biological function and action (100).    
 
1.2.4.1 Gene Ontologies and networks 
The Gene Ontology (GO) nomenclature is powerful for providing functional biological 
analyses to data sets. The GO provides description of gene products under three main 
branches, i.e., biological process, molecular function and cellular component, and a 
gene may be linked to one or several categories under the respective branch (104). The 
ontology is displayed as directed acyclic graphs to visualize the relationship among 
categories (105, 106). There are several tools (Table 1) allowing functional profiling by 
making use of the GO-nomenclature to quantitatively calculate enrichment (over-
representation) of categories among a selected set of differently expressed genes using 
statistical methods such as Fisher’s exact test or Hypergeometric distribution (105-
107). For these analyses, a proper background or reference is crucial, however for 
certain high throughput experiments it may be difficult to select the most appropriate 
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background (107). To this end, larger backgrounds provide more significant p-values. 
Several tools include tests to correct for multiple testing, though these may be quite 
conservative and impair the sensitivity (106, 107). GO-categories are also applicable 
for visualization of transcripts on the microarray with similar functions, displayed by 
the AffyAnnotator tool (Table 1). The GO-nomenclature is constantly developed and 
particularly valuable for identifying biological patterns of already known genes, since 
the results are dependent on annotated genes. To find novel interesting genes and gene 
sets, molecular network analysis is a promising approach. There are several 
commercially available network software that generate networks from a defined set of 
omics data relative to a knowledge database. The Ingenutiy Pathway Analysis (IPA) 
software has primarily been used in these studies and is therefore further elaborated on 
(Table 1). The selected “omics data set” is overlaid onto a global molecular network of 
information in the Ingenuity Pathway Knowledge Base. Network are further 
algorithmically derived based on the connectivity of the input data. Fischer’s exact test 
is applied to determine the significance of associated biological function. Network 
analyses facilitate identification of centrally located and highly connected genes 
compared to ontology-based analyses. Another available molecular network and 
pathway database is the Kyoto encyclopedia of genes and genomes, also applicable for 
enrichment analyses relative to omics data sets (106, 108).    
 
Table 1. Bioinformatics processing tools applied for the omics analyses in this Thesis 
Function Tool URL 
Gene Ontology enrichment analysis  
 
Gene Ontology Tree Machine/ Gene 
Set Analysis Tool Kit 
Database for Annotation, Visualization 
and Integrated Discovery 
 
http://bioinfo.vanderbilt.edu/webgestalt 
 
http://david.abcc.ncifcrf.gov 
Gene Ontology-based visualization of 
transcripts on the microarray  
 
AffyAnnotator http://www.bea.ki.se/jnlp 
Network analysis and key regulator 
identification 
 
Ingenuity Pathway Analysis  http://www.ingenuity.com 
Body-wide gene expression maps 
 
In Silico Transcriptomics 
 
Human Gene Expression Map 
 
http://www.genesapiens.org 
 
http://www.ebi.ac.uk/gxa/array/U133A 
Body-wide proteomics resource  
 
Human Protein Atlas http://www.proteinatlas.org 
Signature evaluation and classification  Signature Evaluation Tool http://microarray.ym.edu.tw/tools/set 
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1.2.4.2 Standards and public omics resources  
Data sharing and standards is an evolving and crucial concept for omics studies to 
enable reuse and integration of available data. The microarray analysis standards 
initiative commenced by the Microarray Gene Expression Data Society, nowadays 
called Functional Genomics Data Society, suggested a minimum of information about a 
microarray experiment, e.g., definition of platform, description of samples, and 
characterization of hybridization and labeling protocol (109). Similar standards are 
available for proteomics data, minimum information about a proteomics experiment 
(110). The application of omics technologies in clinical settings has initiated the 
MicroArray Quality Control consortium involving organizations such as the US Food 
and Drug Administration to establish quality control and standards for data 
comparability across platforms (72). The collection of transcriptomics data into public 
repositories such as the Gene Expression Omnibus and ArrayExpress has enabled the 
development of several novel data mining tools and serve as an excellent basis for 
validation of particularly in vitro data, as well as biological signature reduction (111, 
112). The In Silico Transcriptomics (IST) data base and the Human Gene Expression 
Map (HGEM) are examples of two databases that have assembled expression profiles 
from thousands of microarray experiments (Table 1) (113, 114). The IST contains 
information from 10 000 samples with an average of 11 500 genes per sample 
including 43 healthy tissues, 68 malignant tissues and 64 non-tumor diseases (113). In 
total, data was retrieved from 5 different generation of Affymetrix platforms and 
comparisons were enabled by a novel normalization method (115). Body-wide 
expression profiles can be derived for single genes and co-expression analyses between 
selected genes. The HGEM includes 5372 human samples representing 369 different 
cell and tissue types, disease states and cell lines from one Affymetrix platform (114). 
The data is divided into different biological groups e.g., 96 biological groups that 
include at least ten biological replicates and empower statistical analyses among groups 
for differential expression of single genes. The lack of direct correlation between 
transcript and protein abundance often necessitates assessment of protein expression 
levels for identified genes (94, 95). The Human Protein Atlas (HPA), a proteomics 
database covering more than 50% of all human protein encoding genes contain high-
resolution immunohistochemical images of the protein expression in 46 different 
normal human tissues, 20 different cancer types and 47 different human cell lines 
(Table 1) (97, 116). The simultaneous antibody generation and quality control of this 
proteomics resource is a key feature since the proteomics field has struggled more with 
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unspecific probes compared to the transcriptomics field. To this end, the expanding 
domain of public omics data and novel high throughput resources allow for integration 
of tools and development of approaches to ultimately increase the clinical translation of 
findings in early phases.  
 
 
1.3 BIOMARKER DISCOVERY IS A RAPIDLY EVOLVING RESEARCH 
FIELD 
Realizing the huge diversity among cancer types and impact of inter-individual 
differences, the wish for effective management of cancer patients becomes reformed 
from a “one size fits all” approach to personalized medicine (28, 117). The latter 
strategy requires development of biomarkers, an indicator of a biological state, to allow 
the physician to construct the optimal treatment plan. Extensive cancer biomarker 
discovery efforts have so far yielded minor support to the clinics need for point-of-care 
devices for making the correct cancer diagnosis and person-specific prognosis (118-
120). Limited numbers of biomarker kits are available for clinical testing, and even 
fewer are commercially available (121-123). Apparently lacking for HNSCC, one 
approved gene signature for breast cancer is the 70-gene signature MammaPrint® 
(Agendia, Amsterdam, The Netherlands) that predicts metastasis-free survival (120, 
121). The MammaPrint® signature was recently re-evaluated in independent 
population data sets, and in contrast to initial validation with limited data sets, the 
performance of the signature is now considered overestimated (119). The sensitivity of 
the signature remains at 90%, but the specificity (serving to predict which patients are 
at lower risk of metastasis) is only around 50%. One way to address this problematic 
issue in the biomarker discovery process is the consideration of early referencing of 
results to publically deposited transcriptomics and proteomics data, partly in databases, 
from normal and tumors tissues (98, 113, 114).   
 
1.3.1 Cells lines and tissues in biomarker discovery 
Well known to the cancer community, tissue analyses for cancer biomarker discovery 
are coupled with hurdles (117, 124). The patient can generally only be probed for 
specimen samples once or a limited number of times, and moreover many patients 
receive neo-adjuvant therapy to shrink the tumor before surgical procedures. Although 
partially circumvented by micro-dissection, tumor samples are generally mixed with 
some normal tissue cells and variably with other cell types than of tumor origin (124-
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126). Many tissues like the oral cavity and the head and neck region display large 
structural heterogeneity although considered as one clinical entity (18, 25). Especially 
relevant to HNSCC development, the process of field cancerization, involving 
precancerous genetic alterations without notable histological changes in normal 
appearing tissues, serves to question the appropriateness of applying adjacent and even 
distant normal-appearing tissue as control reference material in the tumor analyses 
(127). Cell lines of tumor and normal tissue origin are promising complementary 
sources to biomarker discovery, providing opportunity for repetitive or even unlimited 
sampling, and abundant material of often relatively larger homogeneity (than tissue) 
(117). Moreover, cell cultures can be manipulated in multiple ways before analysis. 
However, cell lines are naturally poised with the problematic of correctly reflecting in 
vivo functions under selected culture protocols, or might not even establish in culture 
from certain tumors or tumor types (43, 128).  
 
1.3.2 Gene expression profiling of HNSCC for biomarker discovery  
Gene expression profiling of normal and HNSCC specimen and cell lines has generated 
biomarker signatures proposed for tumor classification (129-137). For example, large 
transcriptomics studies of primary versus normal HNSCC tissues have generated 
accurate signatures, including quite large number of genes, however with limited 
independent validation (130, 131, 134, 136). The insufficiency of HNSCC studies with 
outcome data is a limiting factor for the translation of biomarker signatures. Three 
major studies from HNSCC tumors with outcome data are available in the public 
domain, with variable assessment relative to differentiation (129, 133, 137). An effort 
of comprehensive molecular classification of HNSCC identified four sub-types of 
tumors that associated with poor outcome, including with differentiation-related 
changes (129).
 
Another gene expression study in a large HNSCC primary tumor data 
set confirmed inconsistency between the differentiation state and outcome, including 
assessments relative to metastasis (133). The most recent study including normal oral 
epithelium and primary HNSCC associated primarily immune response defects and 
adhesion to survival (137). These studies provide valuable data sets and biomarker 
suggestions for independent validation of in vitro identified genes as potentially 
clinically relevant. 
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1.3.3 Strategies for biomarker discovery  
Data-driven (unsupervised) and knowledge-based (supervised) approaches have 
commonly been applied to anchor gene profiles/signatures with biological responses 
(117). Limited attention have been given to model-driven in vitro strategies, which 
include induction of a biological process by a selected agent or precise culture protocol, 
and utilization of the transcriptional response of the cells to predict tumor properties 
(138). Integrative in vitro strategies of RNA and protein data are likely to increase the 
reliability also within biomarker discovery (139). A need of analyses of cellular 
differentiation states in the context of biomarker discovery is apparent from recent 
genomic analyses of HNSCC (17). Cultures of NOK can be directed to mimic 
physiologically driven processes such as differentiation, e.g., by confluency (contact)-
mediated inhibition of growth or serum-exposure of cultures otherwise routinely grown 
without serum (11, 12, 14-16). Serum-exposure also adds the dimension of assessing 
differentiation from seeing “cancers as wounds that do not heal” (140, 141). These 
protocols allow for testing if impaired contact inhibition and absence of differentiated 
features reflects in vivo generation of tumor mass by hyper-proliferation, adjacent tissue 
invasion and metastasis (29). Central to the hypothesis testing of this thesis work, cell 
lines are viewed as complementary to tissue analysis, addressing the possibility that 
thorough analysis of even a limited number of cell models might reveal data hidden in 
the multitude of current relatively unsuccessful tissue analyses made so far in the field 
of cancer biomarker discovery. The translation from in vitro to in vivo can potentially 
be addressed by standardized serum-free culture protocols, relevant human cell types 
(epithelial cells are the source of the most common human tumor types), control 
cultures from multiple donors in each analysis, unique, well-characterized cell lines, 
and finally, extensive omics profiling and bioinformatics assessment and validation in 
public data sets and databases.  
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2 AIMS OF THIS THESIS 
 
The overall aim of the current thesis project was to elucidate if genomic analyses of an 
in vitro model of normal and transformed human epithelium can elucidate basic 
mechanisms of cancer development and simultaneously generate paradigms/protocols 
generally applicable to cancer biomarker discovery.   
 
An additional important dimension of this Thesis work has been to assess the general 
applicability of the applied in vitro and in silico technologies to alternative methods 
development in environmental medicine. This separate aim considers especially the 
societal need of defining novel cost-effective strategies for analyzing the safety of the 
multiple existing, or to be synthesized, untested chemicals and nanomaterials.  
 
Two major approaches were taken to address oral carcinogenesis, and from a 
bioinformatics perspective, broadly the many sites that encompass head and neck 
squamous cell carcinoma. First, transcriptomics and proteomics data from the cell lines 
were integrated and bioinformatically processed to the Gene Ontology category and 
molecular network level into different gene signatures. Second, attempts of driving 
squamous differentiation (the major biological fate of most normal oral epithelia) were 
made by confluency culture and/or serum exposure of the cell lines within the model 
system. The applicability of the in vitro-generated signatures was validated in multiple 
oral and non-oral data patient data sets, including body-wide transcriptomics and 
proteomics expression databases.   
 
The specific aims were:  
 To compile existing results generated from a start-up cell line model of 
cancer development to facilitate anchoring of the novel “omics”-based 
characterization of the model 
 To establish and characterize novel tumor cell lines under serum-free 
conditions with the intent of potentially expanding the number of entities in 
the model 
 To derive expression profiles for broad overview of the basis for phenotype 
differences related primarily to studies of functional and non-functional cell 
differentiation  
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 To develop “omics-integrative” (combining protein and transcript data) and 
omics model-driven strategies (changing conditions of culture) for applying 
bioinformatics processing tools to biomarker discovery, defining altered 
genes, molecular networks and Gene Ontologies 
 
 To assess broadly that the concepts of tumor biomarker discovery are 
applicable in concept also to the current needs of environmental medicine  
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3 EXPERIMENTAL PROCEDURES 
This section provides an overview of the materials and methods that have been used in 
the present thesis. Detailed descriptions can be found in the Materials and Method 
section of the attached publications and manuscripts. 
 
3.1 CELL CULTURE PROTOCOLS 
Normal oral keratinocytes (NOK) were cultured and transferred in the laboratory-
fabricated serum-free media (EMHA) or the commercial Keratinocyte-SFM (Gibco), 
both which contained growth-promoting supplements like epidermal growth factor and 
pituitary extract, were used interchangeably without detectable differences in growth 
among cell lines or outcome of experiments. Cells in passage 2 or 3 were used 
throughout the experiments. The SV40 T antigen-immortalized oral keratinocyte line 
SVpgC2a and the buccal squamous cell carcinoma line SqCC/Y1, were cultured under 
identical conditions as the NOK. Passages 60-72 were used for SVpgC2a and passages 
125-135 for SqCC/Y1 for all experiments. Characteristics of both cell lines were 
extensively reviewed in PAPER I.       
The tongue squamous cell carcinoma cell line LK0412 was established and cultured 
under conditions identical to the normal counterpart (PAPER IV). Morphology of all 
cells was evaluated under phase-contrast microscopy. For the LK0412 cell line, 
transmission electron microscopy images were also generated. 
 
3.2 ASSESSMENT OF KERATINOCYTE BIOLOGICAL FATES 
3.2.1 Terminal differentiation   
Two established protocols were applied to induce terminal differentiation (TD). Cells 
were grown to 100% confluency and kept confluent for up to four day or by cultivation 
to 100% confluency followed by 5% fetal bovine serum (FBS)-exposure for four days. 
Commitment to TD was determined by assessment of established markers for TD e.g., 
involucrin expression, and by microarray analysis (single gene and Gene Ontology 
level) and immunochemical analysis.     
 
3.2.2 Apoptosis 
Scoring of apoptosis was based on morphological hallmarks i.e., condensed chromatin 
indicative of pyknosis. Cells were formalin-fixed and deposited on coverslips with the 
fluorescent DNA staining dye DAPI or propidium iodide. A florescent microscope was 
   21 
used to analyze and score the cells. Apoptosis was also assessed by microarray analysis 
at the Gene Ontology level. 
 
3.3 ANALYSES OF CELL GROWTH 
Proliferative capacity was assessed by manual counting under the microscope or by the 
colony forming efficiency (CFE) assay. For the CFE assay, cells were seeded at cell 
type specific densities and incubated until surviving colonies could be detected and 
scored under phase contrast.  
 
3.4 TRANSFORMATION ASSESSMENTS 
Anchorage-independent growth was analyzed by soft-agar colony growth over a wide 
range of seeding densities and colonies reaching a pre-selected size were counted under 
phase contrast. NOK did not generate soft agar colonies and was therefore used as a 
negative control. The tumorigenicity in an immunodeficient host was assessed in 
BALB/c (nu/nu) mice subcutaneously injected with cells. Tumor tissue was analyzed 
by routine histopathological protocols. Injection of NOK served as a negative control.  
 
3.5 MUTATION AND “OMICS” ANALYSES  
3.5.1 DNA mutation analysis 
Single strand polymorphism analysis followed by sequence analysis was applied to 
identify mutations in cells and tissues.       
 
3.5.2 Transcriptomics 
Transcriptomics profiles of the cell lines were generated using the oligonucleotide 
Human Genome Focus array (Affymetrix). Raw data files were processed and 
subjected to data mining using the tools listed in Table 1 and in the bioinformatics 
processing section.  
 
3.5.3 Proteomics 
Proteomics profiles were generated using two-dimensional gel electrophoresis (2D-
PAGE) followed by in gel digestion and matrix-assisted laser/desorption ionizing-time 
of flight (MALDI-TOF) mass spectrometry or liquid chromatography-mass 
spectrometry/mass spectrometry for mass finger printing. Western blot analysis was 
applied to verify low abundance proteins and selected transcripts identified from the 
microarray analysis.   
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3.6 BIOINFORMATICS PROCESSING  
3.6.1 Quality control and preprocessing 
All CEL files underwent basic quality control using the simpleaffy package in the R-
environment from the Bioconductor project (http://www.bioconductor.org). Pre-
processing was performed using MAS 5.0 or RMA algorithms.  
  
3.6.2 Assessment of differential gene expression 
Various statistical tests were applied to find significantly differently expressed 
transcripts, e.g., empirical Bayes statistics, Wilcoxon’s signed rank test and 
Significance Analysis of Microarray.  
 
3.6.3 Gene Ontology analyses 
Transcript characterization using the Gene Ontology nomenclature under biological 
process, molecular function and cellular component was applied by the GO-enrichment 
programs Gene Ontology Tree Machine (GOTM) / Gene Set Analysis Tool Kit 
(GSATK) or the Database for Annotation, Visualization and Integrated Discovery. 
Visualization of transcripts on the microarray chip sorted according to the Gene 
Ontology nomenclature was enabled by the AffyAnnotator program.  
  
3.6.4 Network analyses  
The network analysis tool, Ingenuity Pathway Analysis (IPA) was applied to generate 
molecular networks from selected gene products based on information in a curated data 
base encompassing millions of publications. To pinpoint centrally located genes, the 
concept key regulator gene was defined representing a gene with at least three 
interactions with significantly differently expressed transcripts.  
 
3.6.5 Validation in public repositories and databases 
The in vitro-derived gene expression profiles were validated using data selected data 
sets from the public microarray repositories, ArrayExpress and Gene Expression 
Omnibus. The compiled transcriptomics databases In Silico Transcriptomics (IST) and 
Human Gene Expression Map (HGEM) were also applied. The proteomics database, 
the Human Protein Atlas (HPA) was utilized to assess the findings at the protein level. 
Selected findings were also validated in relation to the healthy plasma proteome and 
whole saliva from healthy and oral cancer patients.  
 
   23 
3.6.6 Gene signature evaluation 
The Signature Evaluation Tool (SET) was applied to evaluate and refine the 
discriminatory power of the in vitro-derived signatures using Golub's weighted voting 
algorithm.  
 
3.6.7 Patient survival analyses  
Survival differences among individual genes and gene sets were assessed by Kaplan-
Meier analysis and log-rank test. For individual genes, the median gene expression 
levels were applied to divide samples into two groups. For gene sets, the concept of 
“survival points” was applied, taking each gene into account. Accordingly, points were 
provided to samples with gene expression levels that correlated with good outcome. In 
contrast, gene expression levels that correlated with poor outcome were given no 
points. The survival points were subsequently summarized for each sample. The 
samples were then further divided into two groups based on a cut-off level of half of 
the maximum of assigned points.   
 
3.6.8 The biomarker discovery pipelines  
The “integrative” pipeline included processing of proteomics and transcriptomics data 
from normal and transformed cells. Significantly differently expressed proteins and 
transcripts were integrated by Gene Ontology (GOTM) and network analyses (IPA) via 
the AffyAnnotator tool. In vitro derived profiles were further assessed relative to a 
normal and tumor tissue training data sets for signature evaluation (SET). The herein 
refined signatures were further analyzed relative to various independent oral and non-
oral transcriptomics data, as well as global transcriptomics (IST, HGEM) and 
proteomics (HPA) databases, and saliva and plasma datasets. 
The “model-driven” pipeline included induction of biological processes in the normal 
and transformed cells by means of confluency and/or serum with subsequent 
transcriptomics profiling. Significantly differently expressed transcripts were assessed 
by application of Gene Ontology enrichment (GOTM / GSATK) and network analyses 
(IPA). The derived signatures were then further assessed relative to selected HNSCC 
data sets and signatures including survival data, as well as transcriptomics (HGEM) and 
proteomics (HPA) databases.   
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4 RESULTS 
4.1 PAPER I: ASSESSMENT OF THE START-UP CELL LINE MODEL 
The main goal was to evaluate features of the initial cell line model, to mirror the 
progression of cancer from normal to a fully malignant state, and to broadly identify 
potential application domains, including future biological and bioinformatics modeling.  
 
Preservation of features typical of normal tissue epithelia was demonstrated for NOK, 
e.g., finite life-span, positive response to growth factors, ability to undergo growth 
arrest and TD as a result of stimuli such as TGF-β, Ca2+ and FBS. The SVpgC2a and 
SqCC/Y1 cell lines displayed immortal phenotypes, partly or fully-resistant to 
differentiation-inducing agents. SVpgC2a showed signs of extensive loss of 
differentiation, typical of aggressive tumors. Organotypic cultures of SVpgC2a 
encompassed primarily basaloid non-differentiated cells, while SqCC/Y1 formed 
relatively more preserved normal-appearing mucosal structures. The influence of toxic 
agents was assessed in terms of cellular pathology including growth and cloning, as 
well as mitochondrial and plasma membrane function. Overall, the results displayed 
differences in relation to cell survival, growth and differentiation in the respective 
normal, immortalized and malignant states. Notably, SVpgC2a retained normal tissue 
functions for metabolism of xenobiotics, in contrast to SqCC/Y1, allowing assessment 
of sensitivity to cell transformation by chemicals at different stages of cancer 
progression.   
 
Several components showed the advantage of using this triad of cell lines for 
mimicking oral cancer progression. First, p53 tumor-suppressor protein was functional 
in NOK, but not in SVpgC2a and SqCC/Y1. Second, compared to NOK, the apoptosis 
rate was increased in SVpgC2a and decreased in SqCC/Y1, reflecting results obtained 
from tissue analyses, including a comparison of normal, dysplastic and malignant 
states. Third, immunochemical profiling of cytokeratins in organotypic cultures 
indicated that NOK express the same keratins as the tissue of origin, whereas SVpgC2a 
and SqCC/Y1 showed keratin profiles similar to an oral epithelial dysplasia and well-
differentiated squamous cell carcinomas, respectively. Taken together, comprehensive 
global characterization by omics-technologies would be useful for extended application 
of this cell line model to precisely define the differences between cultured and non-
cultured states.   
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4.2 PAPER II: ESTABLISHMENT OF THE INTEGRATIVE BIOMARKER 
PIPELINE 
The main goal was to derive a bioinformatics approach for integrating proteomics and 
transcriptomics data from the start-up cell line model, and identify perturbed low 
abundance transcriptional regulators. Proteomics analyses of SVpgC2a and SqCC/Y1 
identified 19 differently expressed proteins relative to the normal state, in one or both 
cell lines. Single-gene transcript assessment was feasible for 17 of the 19 proteins by 
microarray analysis, where 9 of the 17 transcript displayed a significant change relative 
to the normal state.  
 
Protein and transcript data were linked in a two-step manner. First, the GOTM tool was 
applied for GO enrichment-analysis; the respective protein profiles enriched eight 
categories in SVpgC2a and four in SqCC/Y1. The AffyAnnotator tool was next applied 
to link the categories with the transcripts, by selecting differently expressed transcripts 
within protein-enriched GO-categories. Overall, the GO-categories captured 582 
transcripts in SVpgC2a and 146 transcripts in SqCC/Y1.  
 
The IPA tool was next applied to investigate if low-abundance transcriptional 
regulators could be identified from the protein-derived transcript and molecular 
networks. Overall, 10 molecular networks were identified for SVpgC2a and 5 networks 
for SqCC/Y1. Cancer, cell death and cellular growth and proliferation were among the 
top three functions for a majority of the networks in both cell lines. A total of 18 genes 
from the networks fulfilled the criteria for consideration as a key regulator. The 
analysis identified CDKN2A, MYC, MYCN, SP1 and TP53 as key regulator genes in 
both cell lines. Additional key regulators included 10 specific key regulators for 
SVpgC2a, and three for SqCC/Y1. Five of the transcription factors were further 
assessed at the protein level by Western blot analysis. Relative to the normal state, the 
expression of Sp1, Sp3 and c-myc was increased in both SVpgC2a and SqCC/Y1. 
Differently, Hif-1ɑ was selectively increased in SqCC/Y1 and p16 in selectively 
increased in SVpgC2a.  
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4.3 PAPER III: MODEL-DRIVEN BIOMARKER PIPELINE: ASSESSMENT 
OF CONFLUENCY-DRIVEN CHANGES 
The main goal was to define transcript profiles of altered responsiveness to the growth-
inhibitory and differentiation inducing effects of cell-cell contact in normal and 
immortalized oral keratinocytes (NOK and SVpgC2a).  
 
Initial analyses of contact inhibition and differentiation-promoting culture of NOK and 
SVpgC2a displayed altered growth, cloning and saturation density in the immortalized 
versus normal state, including absence of differentiated morphological features and 
differential regulation of apoptosis.  
 
Transcript profiles of NOK and SVpgC2a at the sub-confluent and confluent state were 
generated. The six days confluent state of NOK relative to the sparse state generated 
120 differently expressed genes, including categories and networks confirming 
association to development, differentiation and adhesion. Confluent cultures of 
SVpgC2a, displayed 12 differently expressed genes, none corresponding to the changes 
induced by NOK confluency. The SVpgC2a versus NOK transcriptome including 341 
genes enriched altogether 52 GO categories, 18 networks and 39 key regulator genes, 
several of which associated to epithelial-mesenchymal transition.      
 
An “in vitro-derived differentiation-related gene set” (IVDGS) encompassing 476 
genes was constructed from fusion of the three in vitro-derived signatures. Overlap 
analysis of the IVDGS with the Rickman in vivo differentiation and metastasis gene 
sets displayed limited overlapping genes. Evaluation of the IVDGS relative to survival 
data in the same data set identified 31 significant genes. Assessment of these genes 
relative to the HNSCC samples in the HGEM indicated four and 14 genes, that 
displayed concordant changes in tumors with poor and good outcome respectively.  A 
significant impact on overall survival was further obtained in an independent HNSCC 
data set containing 71 samples from applying the 4-gene signature (COX7A1, MFAP5, 
MPDU1 and POLD1).  
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4.4 PAPER IV: ESTABLISHMENT OF AN OSCC CELL LINE UNDER 
SERUM-FREE CONDITIONS 
The main goal was to establish and characterize an oral squamous cell carcinoma 
(OSCC) cell line in conditions devised for NOK, to ultimately extend the initial cell 
line model. The cell line LK0412 was established from a protocol involving four 
passages and two periods of cultural degradation. Subsequently, cultures retained 
identical morphology without noticeable signs of degeneration or crisis for over 50 
passages, including weekly transfers at split ratios of around 1:3. The epithelial 
morphology was verified by phase contrast microscopy, as well as transmission 
electron microscopy at the sub-cellular level displaying cytoplasmic intermediate 
filaments and desmosomal junctions. Immunohistochemical analyses further verified 
consistent presence of cytokeratins among the cells. Growth characterization showed 
that LK0412 exhibited a cloning efficiency of 25-35% and a growth rate of 0.5±0.1 
population doublings per day. Assessment of biological fates compared to NOK 
demonstrated increased indices for proliferation and apoptosis, while the terminal 
differentiation index was decreased. FBS inhibited growth and increased apoptosis, but 
failed to induce terminal differentiation, the latter clearly differed from the response in 
NOK.   
 
A transformed state of LK0412 was indicated from anchorage-independence and 
growth to high saturation density in vitro, including tumor development following 
inoculation of cultures into an immune-deficient host. Histological examination of the 
tumors indicated a moderate differentiation, similar to the histology of the original 
tumor. p53 protein analysis displayed increased levels with a missense mutation 
detectable in both the cell line and original tumor specimen.  
 
Transcriptomics characterization by microarray analyses identified 225 differently 
expressed genes. GO-enrichment analysis generated eleven categories, the majority 
under biological process. Protein-level assessment of selected transcripts previously 
associated to OSCC development indicated altered expression levels in LK0412 
relative to NOK. Moreover, the GO-analysis as well as “top ten deregulated transcripts” 
in LK0412 relative to NOK, suggested potentially novel OSCC biomarker genes such 
as BST2 and ISG15.  
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4.5 PAPER V: MODEL-DRIVEN BIOMARKER PIPELINE: ASSESSMENT 
OF SERUM-DRIVEN CHANGES 
The main goal was to assess the effects of FBS in the extended cell line model, 
including NOK and the transformed keratinocyte cell lines SVpgC2a, SqCC/Y1 and 
LK0412. Accordingly, exposure to 5% FBS induced expected signs of squamous 
differentiation in NOK. The serum-exposure displayed some effects on the transformed 
cell morphologies however overall lacking signs of morphological differentiation.     
 
Transcriptomics profiles were derived to elucidate changes induced from FBS. NOK 
displayed 99 differently expressed genes, 13 GO-categories and six molecular 
networks, including coupling to development, differentiation and injury effects. 
Overall, the transformed cells displayed around 3-fold lower number of differently 
expressed transcripts. In SVpgC2a, 31 genes were differentially expressed, contributing 
to one GO-category i.e., AT-binding. SqCC/Y1 displayed 23 differently expressed 
genes, and 16 GO-categories, encompassing biological functions such as development, 
metabolism, and inflammation and wounding. LK0412 exhibited 29 differently 
expressed genes and 54 GO-categories including, association to cell death, cell 
migration, inflammatory and immune responses, and wounding. Network analyses for 
the transformed cell line variably supported the GO-analyses. Lipid metabolism was 
shared as a top functions for both the normal and transformed states.    
 
A serum-induced gene set (SIGS), encompassing 180 genes was constructed from 
fusing the in vitro-derived gene sets. Assessment of the SIGS to in vivo differentiation 
and metastasis-related gene sets from Rickman displayed limited overlap. Further 
evaluation relative to survival indicated 17 genes with impact on overall survival. 
Assessment of the 17 genes relative to HNSCC in the HGEM showed concordant 
expression for 10 genes relative outcome in the Rickman set. The HPA indicated 
increased intensities for five genes, and decreased intensity of one relative to the 
normal state. Higher than median expression of PDGFRL associated with decreased 
overall survival an independent HNSCC cohort. Significant survival differences were 
not noted for the other genes. Finally, a supervised review of published literature 
implicated previous connection to HNSCC for 12 of the 17 genes.  
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4.6 PAPER VI: EXTENSION AND IN VIVO ASSESSMENT OF THE 
INTEGRATIVE BIOMARKER PIPELINE   
To main goal was to extend and apply the integrative biomarker pipeline to clinical data 
sets. Proteomics analyses identified 27 differently expressed proteins in LK0412 
relative to NOK (Signature A). GO-analysis of these proteins generated 10 categories 
including 119 transcripts (Signature B). Molecular network analyses of these transcripts 
derived six networks, including 11 key regulator genes (the latter Signature C).  
 
The three in vitro-derived Signatures A-C were next assessed relative to a training data 
set encompassing 38 normal and 57 tumor tongue tissues for determination of the  
classification power using the signature evaluation tool. The intact versions of 
Signature A-C, in order, classified the normal and tumor tissues with an overall 
accuracy of 80, 84 and 86%. Evaluation of all variants below the complete set of genes 
in each signature generated refined signatures (termed D, E and F respectively) which 
displayed even higher classification power, i.e., between 83 and 96%. Signature E 
which generated the highest classification power involved the genes, AURKA, 
CENPA, CYP27B1, ISG15, KRT15, MMP9, MX1 and TPX2.  
 
The refined signatures (Signature D-F) were next validated in four independent 
oral/HNSCC data sets. A total of 171 normal and tumor tissue samples were classified 
with accuracies between 82-96% by Signature E. The predictive power of signature E 
was further analyzed relative to non-oral normal and tumor tissues from blood, brain, 
breast, kidney, lung and sarcoma. The non-epithelial tumors were classified correctly to 
only 20% or below. Differently, breast ductal carcinomas and non-small lung cancers 
showed higher classification power around 80%.  
 
The 18 genes included in refined signatures D-F were next explored in two 
transcriptomics databases (IST and HGEM) and the proteomics resource, HPA. 
Elevated expression at the transcript level was found for eight genes in one or both 
transcriptomics databases. Considering immunostaining-based intensity and/or 
quantity, alterations were implied for nine genes in HNSCC relative to the normal state. 
Further analysis of the 18 genes relative to the saliva proteome from healthy and OSCC 
patients, as well as plasma proteome from healthy individuals, identified seven of the 
genes in either saliva, plasma or both.  
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5 DISCUSSION 
Omics technologies have provided extensive information on the expression of suites of 
genes and proteins that are altered in cell lines and tumors. The genetic portrait in 
tissues is not completely reflected by cell lines (128). Questions remain how this can be 
addressed and potentially utilized for reducing the complexity in elucidating 
mechanisms underlying cancer development and biomarker discovery. The studies in 
this thesis aimed at generating broadly applicable integrative and model-induced 
biomarker pipelines based on application and extension of a multi-stage model of 
normal and transformed epithelium.  
 
Evaluation and development of the cell line model provides a basis for biomarker 
discovery 
Well-characterized cell line models are imperative for anchoring gene expression 
changes derived by high-throughput technologies. In PAPER I, the application and 
characteristics of the start-up in vitro model containing NOK, SVpgC2a and SqCC/Y1 
was evaluated. Overall, extensive biochemical and morphological analyses supported 
that the cell lines mirrored aberrances in proliferation, terminal differentiation and 
apoptosis, in a manner similar to cancer progression in vivo (8, 20, 29). The inclusion of 
normal cells especially emphasized the applicability of the model system for 
assessment of terminal differentiation for the purpose of determining retained and 
aberrant normal tissue responses. Given the importance of terminal differentiation as 
the primary biological fate for keratinocytes, the definition of such response is also 
important as a reference for toxicity testing (8, 10). Especially since the majority of 
existing in vitro toxicity tests are utilizing cell lines that cannot turnover in a normal 
manner, and likely reflect early or late stages of cancer development (10). Elaborated 
characterization of this model system by broad “omics” analyses would emphasize the 
understanding of to what extent these human cell lines may reflect a specific cell type, 
tissue or even “strain of human representation” including complex biological endpoints.  
 
The results in PAPER I pointed towards a general lack of serum-free OSCC cell lines 
and the unexploited approach of establishing tumor tissue-derived oral cell lines under 
serum-free conditions. To this end, the start-up model was extended by the first 
reported establishment of an OSCC line (LK0412) under conditions developed for the 
normal counterpart in PAPER IV. The carcinoma origin of LK0412 was verified from 
expression of multiple epithelial characteristics on the genomic and phenotypic level. 
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Histopathological assessments of the resultant tumors in nude mice agreed with that of 
the original tumor, as did the DNA sequence analysis of p53 of the cell line and tumor 
respectively. These findings support that that the resultant cell lined emanated from the 
tumor. Characterization of the LK0412 cell line indicated numerous features associated 
with malignancy, some traits reflecting tumor states which seldom appear in culture. 
For example, the LK0412 cell line emanated from a tumor exhibiting a moderately 
differentiated phenotype, but poorly differentiated states constitute the majority of 
current tumor cell lines (43). The transcriptomics profile of LK0412 was matched to 
previously proposed markers for oral cancer development from two major studies, 
however only seven out of 70 displayed similar deregulated expression, including some 
also at the protein level (22, 142). The LK0412-enriched GO-categories displayed a 
higher degree of overlap to previous OSCC studies e.g., for the categories cell 
adhesion, cell division, cell proliferation, immune response and extracellular 
components (143, 144). This further supports that genes do not act as single units, but 
rather as components and that the perturbation of a category or network may occur 
from varying mechanisms (52). In addition, the unique genotype of LK0412, as well as 
the presence and influences of adjacent normal tissue in tumor analyses may yield 
expression differences (125, 126). Unfortunately, there was not enough material of the 
original tumor to generate a transcriptomics profile to compare the resultant cell line 
with the original tumor specimen. The phenotypic changes in LK0412 also 
corroborated with the transcriptomics-associated GO-categories e.g., deregulated 
“response to stimulus” associated to alterations in genes involved in differentiation. In 
addition, the top differently expressed genes entailed a number of genes that may serve 
as potential novel biomarkers for tongue/oral cancer e.g., BST2 and ISG15. Additional 
serum-free cell lines would be useful to confirm findings implicated by LK0412. 
Furthermore, it would be of particular interest to assess if the expression profiles of 
serum-free generated cell lines potentially display higher similarity to the 
corresponding tissue of origin relative to serum-grown cell lines (128).  
 
The integrative “omics” approach identifies low abundance transcriptional 
regulators and gene signatures for tumor classification  
The initial evaluation of the start-up model in PAPER I inspired omics profiling efforts, 
and in PAPER II the integrative biomarker pipeline was established by combining 
proteomics and transcriptomics data from the transformed cell lines (SVpgC2a and 
SqCC/Y1) relative to NOK. Proteomics profiling identified 19 differently expressed 
proteins in one or both of the transformed cell lines. At the time, eight of the proteins 
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were seemingly novel to oral cancer, following publication of this study, ACAT1, 
PRDX3 and TMP3 have also been linked to oral cancer directly or indirectly (145-
147). The corresponding transcript levels from the microarray analysis were incoherent 
for the majority of the proteins, in line with previous studies displaying a lack of 
overlap among protein and transcript abundance on the single gene level (94, 95, 148). 
The latter finding supported the taken bioinformatics approach since gene expression is 
considered to better mirror protein abundance in terms of functional categories (93). In 
total, 18 key regulator genes were identified from the networks of which five were 
novel to oral cancer at the time, but associated to other malignancies e.g., leukemia, 
sarcoma, breast and renal cancer (149-153). More recently, CEBPA has proven 
association to HNSCC (154). Western blot analysis of selected low-abundance key 
regulator genes confirmed deregulated expression in one or both transformed cell lines 
relative to the normal state for the majority of the assessed transcripts. The transcript 
level changes, either qualitatively or quantitatively, did not agree completely with noted 
changes in protein levels. To this end, the integrative omics approach enabled 
identification of deregulated genes for which probes were not present on the array, e.g., 
SP1 and SP3. The major result derived from the pipeline concept forwarded herein 
indicates that expression changes in only a few abundant proteins can identify key 
changes in cellular pathways.  
 
In PAPER VI application of the integrative biomarker pipeline (PAPER II) was 
extended from analysis of the novel LK0412 cell line (PAPER IV), thus in vitro 
findings consisting of transcript and protein data were validated in independent oral and 
non-oral microarray data sets, as well as public transcriptomics and proteomics 
databases. Proteomic analyses identified 27 abundant proteins (Signature A), of which 
24 displayed increased expression in LK0412 relative to the normal state, which is 
beneficial in terms of being biomarkers. Direct comparisons of the proteins to the 
transcripts showed low coherence similar to findings in Paper II. The GO-enrichment 
analysis of the protein profile provided limited overlap with the transcript analysis, 
however this was not unexpected due to the higher number of assessed transcripts 
compared to proteins. The initial classification of the normal and TSCC samples 
provided accuracies between 80-86%, where Signature C displayed the highest 
accuracy, however following signature reduction, the refined Signature B i.e., Signature 
E showed higher accuracy rates. The classification power was retained for Signature E 
following assessment in four independent oral/HNSCC data sets. Overall, this supports 
the initial idea with the integrative biomarker approach that transcripts within perturbed 
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categories reflect the biology with higher accuracy compared to highly abundant 
proteins. To this end, the proteins are still crucial for identifying important categories. 
Assessment in non-oral cancer data sets overall provided lower classification power in 
non-epithelial cancers, suggesting that the signature has an “epithelial specific” 
component. Moreover, the majority of the eight genes was previously coupled to TSCC 
or could be verified in the transcriptomics, proteomics and/or saliva and plasma protein 
databases as well as in published literature (134, 155-157). Notably, ISG15, an 
interferon-regulated gene (158), was already proposed as a biomarker in PAPER IV 
and was now also included in the most predictive signature. To this end, the integrative 
biomarker approach enabled classification of TSCC specimen from applying “omic” 
profiles from only one cell line to levels comparable or even better than what was 
previously reported for larger gene sets and other studies.      
 
Model-driven approaches for differentiation induction in operative and non-
operative cells identify genes with impact on overall survival in HNSCC 
In PAPER III, a model-driven approach was taken to define gene signatures that 
covered functional and non-functional differentiation by confluency culture of NOK 
and SVpgC2a. Initial, morphological and biochemical assessment of biological fates in 
confluent NOKs indicated that the proliferation potential was decreased, with 
prominent commitment to terminal differentiation, and with only minor involvement of 
apoptosis. Differently, compared to NOK, SVpgC2a consistently showed a lack of 
epithelial morphology, elevated cloning ability, sustained growth potential, absence of 
commitment to terminal differentiation and higher rates of apoptosis. Taking into 
account that minor changes in the balance of biological fates may have significant 
impact on the tissue homeostasis, the concurrent reduction of apoptosis agrees with the 
concept that contact-inhibited proliferation may result in fewer mitotic errors and 
apoptotic abortion of aberrant cells (20, 159). The increased apoptotic frequency in 
SVpgC2a may thus be due to an increased proliferation rate and a perturbed 
differentiation capacity.  
Differentiation-induction in confluent NOKs was confirmed by downstream Gene 
Ontology and network analyses of the differently expressed genes. Accordingly, 
enrichment for “tissue development” and “differentiation”-related categories and 
functions were indicated. The phenotypic comparison of NOK and SVpgC2a provided 
the major contribution to the IVDGS and additionally pointed to a negative regulation 
of differentiation and development-related categories. The latter finding was supported 
by network-based top functions and key regulator analysis that implicated epithelial-
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mesenchymal transition from e.g., decreased expression of E-cadherin (160). The 
IVDGS was next assessed relative to four extensive microarray data sets from HNSCC 
patients (129, 132, 133, 137). Totally, 31 survival-associated genes were identified 
from the Rickman data set, of which 18 genes corroborated with the directional 
changes (14 good outcome and 4 poor outcome) for HNSCC in the HGEM (132, 133). 
To this end, the 4-gene signature (COX7A1, MFAP5, MPDU1 and POLD1) displayed 
significant impact in one of the two independent HNSCC data sets (129, 137). 
Interestingly, the gene MFAP5, encoding a cell motility-stimulating matrix 
glycoprotein was associated to HNSCC for the first time (161). Overall, although all 
signatures did not prove to have predictive power, the results agree with the frequent 
finding that global transcriptomics studies commonly generate highly different 
biomarker signatures (60, 119). Availability of larger data sets for initial training of the 
in vitro signatures, including complementation of additional sets to the body-wide 
expression database, would likely provide higher precision in future analyses. 
Nevertheless, by applying an in vitro-derived signature as starting point, this study was 
able to reveal prognostic genes that were concealed in the initial in vivo analyses.  
 
In PAPER V, a further dimension was added to the model-driven strategy. 
Differentiation-induction was studied again, this time in the extended in vitro model 
and from exposing the cells to FBS. The microscopic and bioinformatics analyses by 
single-genes and GO-categories confirmed TD-induction from this selected serum-
exposure protocol, and the absence of this response in all of the transformed states. 
Interestingly, 35 genes overlapped among the serum and confluency-induced responses 
in NOK, and GO-categorization of these genes enriched only differentiation and 
development-related categories. A subject for future studies, this signature may be 
applicable for assessing the role of differentiation-induction capacity as a toxicity 
outcome. In contrast, serum-induced GOs found in the transformed models pointed to 
other fates such as epithelia-mesenchymal transition in SVpgC2a i.e., the category 
“AT-binding” included altered expression of the architectural transcription factors 
HMGA1 and HMGA2 (162, 163). No overlapping genes were found between the 
serum and confluency response in SVpgC2a. The malignant cell lines SqCC/Y1 and 
LK0412 enriched multiple GOs related to stress and wounding, underscoring that 
malignant cell lines constantly cultured in serum may reflect and enhance their 
constitutive aggressive nature. Lipid metabolism was implied for all models, and 
similar enrichment was also noted from overlay and GO-category analyses of the SIGS 
with a published serum-dependent fibroblast signature that predicted poor outcome in 
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breast cancer (138, 164). This result indicates preserved response among different cell 
types and a role of altered lipid metabolism in malignant transformation (165). Overall, 
taking into account the morphological and gene expression data, serum seems to act 
primarily to drive differentiation in normal oral keratinocytes. In contrast, the loss of 
differentiation capacity in the transformed states couples to changes in the biological 
fate induction typically associated with wound healing. Evaluation of the SIGS to the 
Rickman data set identified 17 genes with impact on survival. The transcriptomics 
database HGEM supported the involvement of 10 of these 17 genes in HNSCC, 
applying a requirement for the same directional change in gene expression as in the 
Rickman data set (114, 133). The slightly higher degree of precision, compared to 
PAPER III may stem from application of the extended in vitro model, reflecting more 
entities and stages in cancer progression. Additional validation of the 17 genes in the 
HPA supported involvement of six of the genes to the protein level. Interestingly, 
PDGFRL displayed significant impact on poor survival in an independent data set 
containing 71 HNSCC, differently to the complete 17-gene based signature set (137). 
The overall results agreed with a role for wound healing-associated effects in cancer 
development, and provided further evidence that model-driven approaches with cell 
cultures can reveal novel biomarkers in clinical samples. 
 
An alternative strategy to biomarker discovery using cell cultures and 
computational biology provide means to replace animal experiments 
 Especially addressed in PAPER I, this project have had a significant component of 
addressing the general applicability of cell lines models and the applied technologies 
also to the need of developing alternative methods under the 3R principle 
(Replacement, Refinement, Reduction). This principle includes the consideration of 
replacing traditional animal experiments and animal-based toxicity testing with in vitro 
and in silico methods (166). Taking this approach, the Thesis work can be viewed as 
“an experimental animal-free biomarker discovery pipeline” useful to the consideration 
of replacing painful and often long-term experiments that are common in cancer and 
toxicity studies with animals. Recent studies have shown that short-term transcriptional 
profiling data serve accurately to predict long-term cancer-related safety of a multitude 
of environmental and industrial chemicals (167). “Standardized serum-free cell culture 
conditions”, “studying both normal and transformed human epithelial cell lines side-by-
side”, “gene expression profiling” and “bioinformatics processing” are lead terms of 
this work that makes the pipeline concepts generally applicable to accurate definition of 
molecular signatures also for chemicals and nanomaterials toxicity, being central areas 
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within the environmental medicine field. Clearly, bioinformatics processing of all 
expressed transcripts in the cell serves as a way to describe and overview cellular 
actions relative to accumulated knowledge in databases (e.g., collected from around 
three millions of publications in the IPA database). Expression of results in terms of 
Gene Ontology constitutes a relatively unexplored way to describe toxicity-induced 
influences on cells. Application of this standardized nomenclature in general toxicology 
research, hazard characterization and eventually risk assessment is bound to facilitate 
the application of computational transcript analysis into safety assessments. 
Additionally, serum-effects were analyzed in models normally cultured without serum 
(PAPER V). The aspiration for increased reproducibility and reduced experimental 
variability that comes with the absence of serum is in line with the societal wish for 
complete removal of animal products from toxicity testing protocols and biomedical 
research generally. Studies with epithelial cells notably correspond to a clinically 
relevant cell type for studying toxicity effects of environmental agents since epithelia 
often serve as a first line of defense. Overall, the research program underlying this 
Thesis was carried out with the consistent aim of assessing the models from this 3R 
perspective.  
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6 CONCLUSIONS 
A unique serum-free three-stage cell line model of cancer development was initially 
shown to exhibit multiple of the phenotypic changes typically noted for cancer 
development in humans. The model was thereafter considered as a start-up model for 
further analyses under systems biology concepts, involving detailed gene expression 
profiling analysis with emphasis on tumor biomarker discovery relative to functional 
and non-functional cell differentiation. Efforts to extend the model with additional 
entities were successful from incorporation of a novel cell line, making the overall 
model progress from a normal-appearing state via an immortalized pre-malignant state 
further into malignant states, including both a well-differentiated and a moderately 
differentiated phenotype. Variable assessments, including visual microscopic, transcript 
and protein expression, as well as functionality-based assays demonstrated impaired 
cell differentiation in the transformed states. This result demonstrated that the model 
could be applied to address tumor biomarker discovery as planned. Cell genotype 
comparisons and comparisons of gene expression changes from influences of different 
culture protocols under two bioinformatics-based pipeline strategies implicated then 
multiple transcripts and proteins as potential tumor biomarkers. Implying true validity 
of the model and for the hypotheses being tested, multiple, but not all, of the 
differentially expressed single genes, pathways, molecular networks and gene 
ontologies had previous association to oral cancer, broadly considering also the 
complete head and neck region. Integration of transcriptomics and proteomics data 
served not surprisingly to enhance the precision of the biomarker discovery effort, 
including naturally to decrease the uncertainty of findings from applying one type of 
omics analysis only. Highly significant to biomarker discovery, the identification of 
only a handful of abundant, easily to detect proteins enabled elucidation of the majority 
of pathways altered by cell transformation. This result included the identification of key 
regulator genes, most of which seem to be transcription factors. Processing of the in 
vitro-derived gene expression profiles via a number of bioinformatics tools, including 
relative publically available cancer patient data sets and body-wide gene expression 
databases, generated the necessary training and validation sets that allowed for accurate 
predictions related to cancer prognosis. Overall, five novel biomarker genes or gene 
signatures (encompassing between 1 to 9 genes) were generated that variably proved to 
accurately distinguish normal tissue from tumor tissue, or alternatively to accurately 
predict outcome in patient-based survival plots. The results therefore proved the 
overarching hypothesis under testing, namely that systems biology studies under the 
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concept of in vitro modeling of cancer development can serve to identify tumor 
biomarker genes hidden in complex analysis of cancer patient material. Overall, an 
extended cell culture model for cancer development was derived, with potential to 
serve in multiple manners to future wishes of addressing both normal and aberrant cell 
functions. Especially, the model proved to elucidate further the complex mechanisms of 
biological fate induction in normal and cancer tissues, as well as to generally 
demonstrate the usefulness of attempting translational application of in vitro results all 
the way to the human situation. Viewing and analyzing thoroughly human cell lines as 
unique entities seems to have great potential for contributing valuable information to 
the many issues and complexities that underlie the future need of personalized medicine 
in the treatment of human cancer. 
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